CASI Wins HKIAC Arbitration Award Topping RMB 100 Million Against Juventas
CASI•Award exceeds RMB 100 million
The award covers wasted costs, interest from the termination date, arbitration costs, and most legal fees, totaling well over RMB 100 million.
HKIAC tribunal rules in CASI's favor
CASI Pharmaceuticals won a final arbitration award against Juventas at the Hong Kong International Arbitration Centre over CNCT-19 commercialization agreements.
The tribunal rejected all Juventas breach claims, ruling Juventas wrongfully terminated the agreements in March 2024.
